Article

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell Transplantation

2026-05-21

Abstract excerpt

<title>Abstract</title> <p>Background: Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed CAR T-cell therapy approved for relapsed/refractory (R/R) mantle cell lymphoma (MCL) based on the pilot study ZUMA-2. Since then, several US and European real-world studies have demonstrated comparable efficacy outcomes. However, these reports have also suggested potentially higher rates of acute toxicitie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51ee61ff-9f0e-52fa-93c0-57d150fac001
DOI: 10.21203/rs.3.rs-9688623/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationDOI 10.21203/rs.3.rs-9688623/v1Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationSemantic proximity Read

Your chemo is no good here: management of high-risk MCL.Semantic proximity Read

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in CanadaSemantic proximity Read

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experienceSemantic proximity Read

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read